L. Westerink, MSc

Faculty of Medical Sciences

Telephone:

+31 50 361 6977

E-mail:

l.westerink01 umcg.nl

ORCID Research Portal

Publications

Trends in NICE technology appraisals of non-small cell lung cancer drugs over the last decade

Westerink, L., Wolters, S., Zhou, G., Postma, A., Boersma, C., van Boven, J. F. M. & Postma, M. J., 30-Aug-2024, (E-pub ahead of print) In: European Journal of Health Economics.

Research output: Contribution to journal › Article › Academic › peer-review

Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

Westerink, L., Nicolai, J. L. J., Postma, M. J., van Boven, J. F. M. & Boersma, C., Sept-2022, In: PharmacoEconomics - open. 6, p. 647–656 10 p.

Research output: Contribution to journal › Article › Academic › peer-review

Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations

Westerink, L., Nicolai, J. L. J., Samuelsen, C., Smit, H. J. M., Postmus, P. E., Griebsch, I. & Postma, M. J., 1-Aug-2020, In: European Journal of Health Economics. 21, 6, p. 931-943 13 p.

Research output: Contribution to journal › Article › Academic › peer-review

COST-EFFECTIVENESS OF NINTEDANIB IN PATIENTS WITH PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE (PF-ILD) IN THE NETHERLANDS

Westerink, L., Nicolai, J., Postma, M., van Boven, J. F. M. & Boersma, C., 1-Dec-2020, In: Value in Health. 23, p. S716-S717 2 p.

Research output: Contribution to journal › Meeting Abstract › Academic

Ontwikkelingen van farmaco-economisch onderzoek vanuit historisch perspectief

Westerink, L., Dvortsin, E. & Postma, M. J., 19-Jul-2019, In: Pharmaceutisch Weekblad. 154, 29-30, p. 21-26 6 p.

Research output: Contribution to journal › Article › Academic › peer-review

All (5) publications

View full research profile